Showing 1 - 4 results of 4 for search 'Meliessa Hennessy', query time: 0.03s Refine Results
  1. 1
    Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma

    Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with... by Murtuza Bharmal, Sandra Nolte, Mickaël Henry-Szatkowski, Meliessa Hennessy, Michael Schlichting

    Published 2020-05-01
    Get full text
    Article
  2. 2
    How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial

    How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical t... by Murtuza Bharmal, Isabelle Guillemin, Alexia Marrel, Benoit Arnould, Jérémy Lambert, Meliessa Hennessy, Fatoumata Fofana

    Published 2018-06-01
    Get full text
    Article
  3. 3
    Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

    Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial by Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem

    Published 2018-01-01
    Get full text
    Article
  4. 4
    S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

    S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL by Elias Jabbour, Hagop Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Leonard, David Gomez, Maria Baer, Carlo Gambacorti-Passerini, James Mccloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice Wang, Meliessa Hennessy, Niti Patel, Alexander Vorog, Bingxia Wang, Huilan Yao, Tammie Yeh, Josep Maria Ribera

    Published 2023-08-01
    Get full text
    Article

Search Tools: